NEWS | July 27, 2020

COVID-19 commentary by Harvard-UC Davis team: most downloaded paper in history of CMR Journal

A research commentary on how a drug discovered in the laboratories of Professors Charles Serhan of Harvard Medical School and Bruce Hammock of UC Davis may control the body's inflammatory response to COVID-19 is the most downloaded article in the history of the journal Cancer Metastasis and Reviews (CMR), a Springer Nature publishing group. The drug stabilizes two groups of natural chemical mediators. 

As of July 8, the commentary, “Inflammation Resolution: a Dual-Pronged Approach to Averting Cytokine Storms in COVID-19?”—the work of a nine-member team of Harvard University and UC Davis researchers—has been downloaded 11,444 times since its publication on May 8, 2020. In comparison, the paper has already received more than twice as many downloads as the journal's most-downloaded paper for all of 2019. You can access it online here.

Editor-in-Chief Kenneth Honn, who selected the commentary as the top paper of the month, said it drew more downloads the first week of publication than any other in the journal's history. The work is based on more than 40 years of eicosanoid research from the Hammock lab and Serhan lab, respectively.

“COVID-19 results in excessive inflammation and a cytokine storm caused by the human body's reaction to the SARS-CoV-2 virus,” said lead author Dipak Panigrahy, a Harvard University physician and researcher who collaborates with the Hammock laboratory.

“We believe it holds promise to combat the inflammation involved with this disease,” said co-author Hammock, who holds a joint appointment with the Department of Entomology and Nematology and the UC Davis Comprehensive Cancer Center.  “It hit me in March that what we really need to do is not so much block cytokines as to move upstream to modulate them and resolve them rather than block inflammation.”

“We can increase the concentration of natural pro-resolving mediators termed EETs which act on a biological system to produce other pro-resolution mediators which modulate inflammation and actively resolve the process,” explained Hammock, who founded the Davis-based company EicOsis Human Health LLC, to bring the inhibitor to human clinical trials, which are underway in Texas.

The co-authors include physician-researcher Irene Cortés-Puch of the Division of Pulmonary, Critical Care and Sleep Medicine at UC Davis. Learn more here